Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 551 - 600 out of 6,862

Document Document Title
WO/2012/116151A2
Compounds of formula II are described, wherein D, n, Ra, Rb, and Rc are as herein defined, along with pharmaceutical compositions and methods of using compounds of formula II for treating or reducing the risk of peritoneal carcinomatosis...  
WO/2012/114347A1
Disclosed herein is a compound of formula (A), its salts, enantiomers, and diastereomers thereof; wherein, Rl and R2 can be (C1-C6) alkyl groups, a phenyl group, a (C5-C7) cycloalkyl groups; X and Y individually selected from H, -N02, -N...  
WO/2012/114350A1
The present invention provides a process for preparing 5-(acetylamino)-4- [(aminoiminomethyl)amino]-2,6-anhydro-3,4,5-trideoxy-D-glyce ro-D-galacto-non- enonic acid Formula (I), which process comprises reducing compound of Formula (IV) b...  
WO/2012/103777A1
Disclosed is a compound isolated from monascus purpureus, a preparation method therefor and uses thereof. Specifically, the compound is as represented in formula I, or pharmaceutically acceptable salts thereof, where R1 is selected from ...  
WO/2012/104659A1
A compound of Formula (I), and its pharmaceutically acceptable salt or salts and physiologically hydrolysable derivatives in free form or salt form: wherein R1 is independently selected from F, CI, Br, CN, NH2, OH, CHO, COOH, oxo, C1-4al...  
WO/2012/105321A1
Provided is a photoresist composition which contains a polymer compound that contains, as a constituent unit, a specific methacrylic acid ester derivative. The photoresist composition is capable of forming a photoresist pattern that has ...  
WO/2012/101442A1
The invention provides a method of forming an iron hydroxypyrone compound comprising reacting a hydroxypyrone with a non-carboxylate iron salt in an aqueous solution, and precipitating the iron hydroxypyrone compound from the aqueous sol...  
WO/2012/090177A2
Compounds of Formula (I) along with processes for their preparation that are useful for treating, preventing and/or managing the diseases, disorders, syndromes or conditions associated with the modulation of cannabinoid (CB) receptors. M...  
WO/2012/090220A1
The present invention relates to compounds of the general formula (I), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods for their preparation, use ...  
WO/2012/085221A1
The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt thereof, a tautomer, a stereoisomer or a mixture of stereoisomers in any proportion, in particular a mixture of enantiomers, and particularl...  
WO/2012/085191A1
The present invention relates to a novel form of pravastatin, notably pravastatin sodium, and a method for the preparation of a novel form of pravastatin.  
WO/2012/085645A1
Polymorphs of 3-chloro-4[(2R)-2-(4-chlorophenyl)-4-[(1R)-1-(4-cyanophenyl) ethyl]-1- piperazinyl]-benzonitrile are disclosed, as well as pharmaceutical compositions comprising said polymorphs, methods of using the polymorphs, and a proce...  
WO/2012/083953A1
The invention relates to compounds of general formula I wherein R is heteroaryl optionally substituted by R7; or R is heterocycloalkyl or heterocycloalkenyl, optionally substituted by R8; or R is X wherein X is -NR11R12; and pharmaceutic...  
WO/2012/080050A1
Provided herein are solid forms of 4-[4-(4-chlorophenoxy)-benzenesulfonyl-methyl]- tetrahydropyran-4-carboxylic acid hydroxyamide, processes of preparation and pharmaceutical compositions thereof. Also provided are methods of their use f...  
WO/2012/073214A2
Compounds having the general formula (I) and their biological applications.  
WO/2012/065905A1
The present invention relates to cyanoenamine derivatives, their process of preparation, intermediate compounds, their use as fungicide active agents, particularly in the form of fungicide compositions, and methods for the control of phy...  
WO/2012/060185A1
The present invention is a method for producing ester from ketone or aldehyde that is a reactant, using hydrogen peroxide by Baeyer-Villiger oxidation reaction, wherein as a catalyst, M(BAr4)n (M is an alkali metal or an alkali-earth met...  
WO/2012/061012A2
Compounds of Formula I are described, along with methods of using such compounds for the treatment of cancer and pharmaceutical formulations thereof.  
WO/2012/049460A1
The present invention provides compounds of the formula Formula I or a salt thereof: and the uses of such compounds for the treatment of a disease or disorder involving oxidative damage, for preventing UV damage to the skin of a mammal a...  
WO/2012/049346A1
The invention relates to a compound having formula (I), the hydroxy acid thereof, the pharmaceutically acceptable salts of said hydroxy acid and prodrugs and pharmaceutically acceptable solvates of the compound and the hydroxy acid form ...  
WO/2012/046771A1
The inventors have intensively studied on compounds that have Aβ42 production inhibitory activity and have found that a compound (I) of the present invention, wherein a carboxylic acid or a tetrazole group is bonded to a cycloalkane moi...  
WO/2012/042482A1
The present invention relates to the synthesis of analogous compounds of funicone, some of which are not found in nature, which comprises the preparation of compounds having general formula (III) and (IV) and the subsequent coupling reac...  
WO/2012/033815A1
The invention provides a compound of formula (I): or a salt thereof, wherein R1 -R4 have any of the values described in the specification, as well as compositions comprising a compound of formula (I). The compounds are useful as antibact...  
WO/2012/029942A1
Provided is a compound represented by formula (1) or a pharmacologically acceptable salt thereof. (In the formula, A represents a C6-10 arylene group or the like; R1a, R1b and R1c each independently represents a hydrogen atom, a halogen ...  
WO/2012/025701A1
Compounds selected from the following group and their salts are inhibitors of HDAC activity, useful in the treatment of, inter alia, cell proliferative disease and inflammation: Cyclopentyl 1 -[({5-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1...  
WO/2012/023582A1
Provided is a compound for inhibiting abnormal glucose intolerance and postprandial hyperglycemia in diabetic patients by inhibiting the activity of sodium-glucose transporter 1 (SGLT 1) and the absorption of glucose. Specifically provid...  
WO/2012/023600A1
Provided is a compound for inhibiting abnormal glucose intolerance and postprandial hyperglycemia in diabetic patients by inhibiting the activity of sodium-glucose transporter 1 (SGLT 1) and the absorption of glucose. Specifically provid...  
WO/2012/023598A1
Provided are a highly stable crystal of (1S)-1,5-anhydro-1-[5-(4-{(1E)-4-[(1-{[2-(dimethylamino)- ethyl]amino}-2-methyl-1-oxopropan-2-yl)amino]-3,3-dimethyl-4 -oxobut-1-en-1-yl}benzyl)-2-methoxy-4-(propan-2-yl)phenyl]-D -glucitol and a p...  
WO/2012/024276A1
Ethoxylated fatty acid mono-ester(s) of sorbitan with a fatty acid chain length from 8 to 14 and an overall degree of ethoxylation from 7 to 16 are new (though related to the polysorbates). These compounds are useful as adjuvants in agro...  
WO/2012/019428A1
Benzohydrol derivatives of formula (I), a preparation method, pharmaceutical compositions and pharmaceutical use thereof are disclosed in the invention. The derivatives can be used as rennin inhibitors to prepare the drugs for the treatm...  
WO/2012/020643A1
Provided is a liquid crystalline compound having stability to heat, light and the like, a wide temperature range of a nematic phase, a small viscosity, a suitable optical anisotropy, and a suitable elastic constant K33, as well as having...  
WO/2012/018656A2
The present invention provides for a demulsifying composition comprising a blend of a) an emulsion; and b) a demulsifying-effective amount of a silicon containing co-polymer. The present invention also provides for a method for separatin...  
WO/2012/015790A1
Esters of O-substituted hydroxy carboxylic acids are provided having Formula 1, or 2, or both Formulas 1 and 2: wherein R and R1 are independently selected from the group consisting of substituted and unsubstituted, branched- and straigh...  
WO/2012/012465A1
Provided are methods and intermediates for preparing diastereomerically pure phosphoramidate prodrugs of nucleosides of Formulas (la) and (lb): The compounds of Formula la and lb are useful for the treatment Hepatitis C infections.  
WO/2012/012776A1
Provided are methods for treating Paramyxoviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula (I): wherein the 1 ' position of the nucleoside sugar is substituted. The compounds, comp...  
WO/2012/008435A1
Disclosed is a novel biaryl amide derivative represented by formula (1) and having an affinity for the aldosterone receptor; also disclosed is a pharmaceutically acceptable salt thereof. (In the formula, A is any of the groups represente...  
WO/2012/008765A2
The present invention relates to the compound of chemical formula I, to the pharmaceutically acceptable salts thereof or hydrates thereof, to a pharmaceutical composition containing the compound as an active ingredient for treating or pr...  
WO/2012/003811A1
C-aryl glucosides which are inhibitors of sodium dependent glucose transporters found in the intestine and kidney (SGLT2), shown as formula I, a pharmaceutical composition and pharmaceutical combination.  
WO/2012/003497A1
The invention provides compounds of formula (I): or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula (I), interme...  
WO/2012/000608A2
The present invention relates to novel beta-aminoaldehyde derivatives of the formulae (I), (II) and (III), in which the substituents R1 to R5 and A have the meaning given in the description, to a novel process for their preparation, to i...  
WO/2011/159067A2
The present invention relates to a novel compound with thiazole ring having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney, and a pharmaceutical composition compr...  
WO/2011/158950A1
To provide a tetrahydropyranyl compound represented by General Formula (1) below: General Formula (1) where X denotes any one of a substituted or unsubstituted alkyl group, an oxygen atom, and a substituted or unsubstituted aromatic hydr...  
WO/2011/156655A2
Compounds that bind the glucagon-like peptide 1 receptor (GLP-1) receptor are provided including compounds which are modulators of the GLP-1 receptors and compounds which are capable of inducing a stabilizing effect on the receptor for u...  
WO/2011/154330A1
Process for the preparation of 2-substituted 4-hydroxy-4-methyltetrahydropyrans of the formula (I) where the radical R1 is a straight-chain or branched alkyl or alkenyl radical having 1 to 12 carbon atoms, an optionally alkyl-substituted...  
WO/2011/151348A1
This invention relates to heterocyclic amino acid derivatives suitable for labeling or already labeled with 18F or 19F, methods of preparing such compounds, compositions comprising such compounds, kits comprising such compounds or compos...  
WO/2011/149339A1
The present invention relates to a method for preparing caprolactone, comprising converting 5-hydroxymethyl-2-furfuraldehyde by hydrogenation into at least one intermediate compound selected from the group of 2,5-tetrahydrofuran-dimethan...  
WO/2011/147311A1
Compounds represented by formula (I), preparative method thereof and pharmaceutical compositions containing them and use thereof as immuno-regulation agents. The compounds can treat immunologic derangement, immunosuppression, hypoimmunit...  
WO/2011/147919A1
The invention relates to a method for producing 4-hydroxy-4-methyl-tetrahydropyran substituted in the 2-position by reacting 3-methylbut-3-en-1-ol (isoprenol) with the corresponding alkene aldehydes in the presence of a very acidic ion e...  
WO/2011/150288A1
Provided are prodrugs of pyrrolo[l,2-f][l,2,4]triazin-7-yl nucleoside phosphates wherein the 1 ' position of the nucleoside sugar is substituted with CN. The compounds, compositions, and methods provided are useful for the treatment Hepa...  
WO/2011/145669A1
Disclosed are the compound represented by formula (I) which is useful as a therapeutic or prophylactic agent for various partial and/or generalized epileptic seizures, or a salt thereof. [In the formula, ring A and ring B independently r...  

Matches 551 - 600 out of 6,862